¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • curative effect
    Ä¡·áÈ¿°ú
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
  • cavitation effect
    °øµ¿È¿°ú
  • ceiling effect
    ÃÖ°íÈ¿°ú
  • delayed effect
    Áö¿¬È¿°ú
  • detergent effect
    ¼¼Ã´È¿°ú, Á¤È­È¿°ú
  • deterministic effect
    È®Á¤ÀûÈ¿°ú
  • diabetogenic effect
    ´ç´¢º´À¯¹ßÈ¿°ú
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • effect
    È¿°ú
  • greenhouse effect
    ¿Â½ÇÈ¿°ú
  • healthy worker effect
    °Ç°­±Ù·ÎÀÚÈ¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
  • cavitation effect
    °øµ¿È¿°ú
  • ceiling effect
    ÃÖ°íÈ¿°ú
  • clasp-knife effect
    Á¢´ÂĮȿ°ú
  • cohort effect
    ÄÚȣƮȿ°ú
  • combined effect
    º´¿ëÈ¿°ú
  • concentration effect
    ³óµµÈ¿°ú
  • cumulative effect
    ´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
  • curative effect
    Ä¡·áÈ¿°ú
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • delayed effect
    Áö¿¬È¿°ú
  • detergent effect
    Á¤È­ÀÛ¿ë
  • deterministic effect
    È®Á¤Àû¿µÇâ
  • diabetogenic effect
    ´ç´¢À¯¹ßÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glucose oxydation fermentation test
    Æ÷µµ´ç»êÈ­¹ßÈ¿½ÃÇè.
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • glucose transport protein unit
    Æ÷µµ´ç ¿î¹Ý ´Ü¹é ´ÜÀ§(GLUT)
  • glucose-6-phosphatase
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ¿À½º-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀ̵å·ÎÀú³×À̽º
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glucose-cysteine agar
    ±Û·çÄÚ¿À½º-½Ã½ºÅ×ÀÎ
  • glucose-galactose
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺
  • glucose-galactose malabsorption
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺Èí¼öÀå¾Ö
  • random plasma glucose test
    ÀÓÀÇ(Àû)Ç÷Àå´ç½ÃÇè
  • Bernouilli effect
    º£¸£´©ÀÌ È¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glucose oxydase test
    Æ÷µµ´ç»êÈ­È¿¼Ò¹ý.
  • glucose oxydation fermentation test
    Æ÷µµ´ç»êÈ­¹ßÈ¿½ÃÇè.
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • glucose transport protein unit
    Æ÷µµ´ç ¿î¹Ý ´Ü¹é ´ÜÀ§(GLUT)
  • glucose-6-phosphatase
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀ̵å·ÎÀú³×À̽º
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ¿À½º-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glucose-cysteine agar
    ±Û·çÄÚ¿À½º-½Ã½ºÅ×ÀÎ
  • glucose-galactose
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺
  • glucose-galactose malabsorption
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺Èí¼öÀå¾Ö
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • electrochromic effect
    Àü±âº¯»ö È¿°ú(ï³Ñ¨Ü¨ßäüùÍý)
  • electrophoretic effect
    Àü±â¿µµ¿ È¿°ú(ï³Ñ¨ç¶ÔÑüùÍý)
  • electroviscous effect
    Àü±âÁ¡¼º È¿°ú(ï³Ñ¨ïÄàõüùÍý)
  • enhancement effect
    Áõ°­ È¿°ú (ñòË­üùÍý)
  • extrinsic Cotton effect
    ¿ÜÀμº(èâì×àõ) ÄÚÆ° È¿°ú(üùÍý)
  • Faraday effect
    ÆÐ·¯µ¥ÀÌ È¿°ú(üùÍý)
  • field effect
    ÀåÈ¿°ú(íÞüùÍý)
  • founder effect
    ½ÃÁ¶ È¿°ú(ã·ðÓüùÍý)
  • Haldane effect
    Ȧµ¥ÀÎ È¿°ú(üùÍý)
  • heterotropic effect
    ÀÌÁú È¿°ú(ì¶òõüùÍý)
  • homoptropic effect
    µ¿Áú È¿°ú(ÔÒòõüùÍý)
  • hydrophobic effect
    ¼Ò¼ö È¿°ú(áÂâ©áÂâ©)
  • hyperchromic effect
    Èí±¤Áõ°¡ È¿°ú (ýåÎÃñòÊ¥üùÍý)
  • hypochromic effect
    Èí±¤ °¨¼Ò È¿°ú(ýåÎÃÊõá´üùÍý)
  • induction effect
    À¯µµÈ¿°ú(ë¯ÓôüùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • piezoelectric effect
    ¾ÐÀüÈ¿°ú
  • radiation effect
    ¹æ»ç¼±È¿°ú
  • radio-frequency thermal effect
    °íÁÖÆÄ¿­È¿°ú
  • reverse piezoelectric effect
    ¿ª¾ÐÀüÈ¿°ú
  • RF antennae effect
    °íÁ֯ľÈÅ׳ªÈ¿°ú
  • shielding effect
    Â÷ÆóÈ¿°ú
  • siphonage effect
    ½ÎÀÌÆùÈ¿°ú
  • spatial presaturation effect
    °ø°£ÀüÆ÷È­È¿°ú
  • spin phase effect
    ½ºÇÉÀ§»óÈ¿°ú
  • T1 shortening effect
    T1´ÜÃàÈ¿°ú
  • T2 shortening effect
    T2´ÜÃàÈ¿°ú
  • volume averaging effect
    ¿ëÀûÆò±ÕÈ­È¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CPE cardiac pulmonary edema; chronic pulmonary emphysema; clinical progress exercise; compensation, pens...
CRE cumulative radiation effect; cyclic adenosine monophosphate-response element
DEF decayed primary teeth requiring filling, decayed primary teeth requiring extraction, and primary tee...
DEFNT dose-effect factor for normal tissue
DEFT dose-effect factor for tumor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LOEL Lowest Observed Effect Level
LOEC Lowest observed effect concentrations
ME McCollough Effect
NOAEL No Observable Adverse Effect Level
NOEL No Observable Effect Level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • entry slice effect
    À¯ÀÔ ´Ü¸é È¿°ú
  • first pass effect
    ÀÏÂ÷ Åë°ú È¿°ú
  • focus effect
    ÃÐÁ¡ È¿°ú
  • harmful effect
    À§ÇØ ÀÛ¿ë
    À§ÇèÇÑ ÀçÇØ. Á¶Á÷À̳ª »ý¸íü¿¡ ÇØ·Î¿î ¿µÇâÀ» ³¢Ä¡´Â ÀÛ¿ë.
  • heel effect
    Èú È¿°ú
    ¾ç±Ø °æ»ç °¢µµ¿¡ µû¸¥ È¿°ú.
  • indirect effect
    °£Á¢ È¿°ú
  • isotopic effect
    µ¿À§ ¿ø¼Ò È¿°ú
  • lethal effect
    Ä¡»ç È¿°ú
  • longitudinal effect
    Á¾ È¿°ú, Á¾Àû È¿°ú
  • misregistration effect
    ¿Àµî·Ï È¿°ú
  • modulating effect
    Á¶Àý È¿°ú
  • muscle effect
    ±ÙÀ° È¿°ú
  • myocardium,aging effect
    ³ëÈ­ Çö»ó
  • Nagler effect
    ³ª±Û·¯ È¿°ú
  • nonallergic side effect
    ºñ¾Ë·¹¸£±â¼º ºÎÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
glucose dehydrogenases <enzyme> D-glucose:1-oxidoreductases. Catalyses the oxidation of d-glucose to d-glucono-gamma-lactone and reduced acceptor. Any acceptor except molecular oxygen is permitted.
Registry number: EC 1.1.1.
(12 Dec 1998)
glucose-fructose oxidoreductase <enzyme> Isolated from zymomonas mobilis; catalyses the formation of sorbitol and glucono-delta-lactone from glucose and fructose; enzyme contains tightly bound nadp+
Registry number: EC 1.1.99.-
(26 Jun 1999)
glucose intolerance A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases.
(12 Dec 1998)
glucose isomerase <enzyme> An isomerase enzyme which converts the sugar glucose into the sugar fructose. Fructose is a structural isomer of glucose.
(09 Oct 1997)
glucose oxidase <enzyme> An enzyme which converts glucose into gluconic acid and hydrogen peroxide (H2O2). It is used to help diagnose diabetes by determining if glucose is present in the patients urine, if the glucose is present, the hydrogen peroxide produced in the reaction can be detected by reacting it with an indicator to change the colour of the urine.
(09 Oct 1997)
glucose oxidase method <chemical pathology> A highly specific method for measurement of glucose in serum or plasma by reaction with glucose oxidase, in which gluconic acid and hydrogen peroxide are formed.
(05 Mar 2000)
glucose oxidase paper strip test <chemical pathology> A qualitative test for glucose in the urine, in which glucose is oxidised to gluconic acid by glucose oxidase; a specific test, unless ascorbic acid is present.
(05 Mar 2000)
glucose oxyhydrase <enzyme> An enzyme which converts glucose into gluconic acid and hydrogen peroxide (H2O2). It is used to help diagnose diabetes by determining if glucose is present in the patients urine, if the glucose is present, the hydrogen peroxide produced in the reaction can be detected by reacting it with an indicator to change the colour of the urine.
(09 Oct 1997)
glucose-phosphate isomerase <enzyme> An enzyme that catalyses the reversible interconversion of d-fructose 6-phosphate and d-glucose-6-phosphate; a part of glycolysis and gluconeogenesis; glucosephosphate isomerase deficiency is an inherited disorder resulting in liver glycogenesis and haemolytic anaemia.
Synonym: hexosephosphate isomerase, phosphohexomutase, phosphohexose isomerase.
(05 Mar 2000)
glucose phosphomutase <enzyme> An enzyme that catalyses the conversion of alpha d-glucose 1-phosphate to alpha d-glucose-6-phosphate.
Chemical name: alpha-D-Glucose 1,6-phosphomutase
Registry number: EC 5.4.2.2
(12 Dec 1998)
glucose related protein <protein> One of the stress related proteins: identical to endoplasmin.
(18 Nov 1997)
glucose solution, hypertonic Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent.
(12 Dec 1998)
glucose tolerance factor A water-soluble complex containing chromium needed for normal glucose tolerance.
(05 Mar 2000)
glucose tolerance test <chemical pathology, investigation> A special test where the blood glucose is measure in intervals after a glucose-rich meal is taken, a test used for diagnosing diabetes.
(27 Sep 1997)
glycerol-3-phosphate - glucose phosphotransferase <enzyme> Catalyses the formation of glycerol and glucose-6-phosphate
Registry number: EC 2.7.1.142
Synonym: gro3p-glucose transphorylase, glycerol 3-phosphate-glucose transphorylase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á